An Act To Update the Maine Insurance Code To Maintain Conformance with Uniform National Standards
PART A
Sec. A-1. 24 MRSA §2306, as amended by PL 1997, c. 592, §3, is further amended to read:
§ 2306. Reports
Annually, on or before March 1st, every Every corporation organized under this chapter shall file in the office of the superintendent a statement annual and quarterly financial statements substantially similar to those required of health insurers under Title 24-A, sections 423, 423-A and 423-D verified by at least 2 of the principal officers of that corporation showing its condition on the previous December 31st. The statement must be on an annual or quarterly statement blank of the National Association of Insurance Commissioners for use by nonprofit hospital or medical service corporations, be prepared in accordance with the association's annual or quarterly statement instructions, follow practices and procedures prescribed by the association's accounting practices and procedures manual and be accompanied by any useful or necessary modification or adaptation and any additional information required by the superintendent. The superintendent may by rule or order require the filing of more frequent reports.
A nonprofit hospital or medical service corporation that controls and operates a health maintenance organization as a division or line of business of the corporation shall file on a continuing basis any additional periodic financial reports required by the superintendent by rule Title 24-A, section 4208.
Sec. A-2. 24 MRSA §2317-B, sub-§§1-A and 1-B are enacted to read:
Sec. A-3. 24 MRSA §2317-B, sub-§16-B is enacted to read:
Sec. A-4. 24-A MRSA §423-A, as enacted by PL 1985, c. 330, §6, is amended to read:
§ 423-A. Interim financial reporting requirements
Sec. A-5. 24-A MRSA §423-G is enacted to read:
§ 423-G. Corporate governance annual disclosure
(1) If the CGAD is completed at the insurance group level, and this State is not the group's lead state, the CGAD must be filed with the chief insurance regulator of the lead state in accordance with the laws of the lead state, and a copy must be filed with the superintendent if requested by the superintendent.
(2) If the CGAD is completed at the legal entity level or if this State is the group's lead state, the CGAD must be filed with the superintendent.
(1) At which the domestic insurance carrier's or insurance group's risk appetite is determined;
(2) At which the earnings, capital, liquidity, operations and reputation of the domestic insurance carrier are overseen collectively and at which the supervision of those factors is coordinated and exercised; or
(3) At which legal liability for failure of general corporate governance duties is placed.
If the domestic insurance carrier or insurance group determines the level of reporting based on the 3 criteria under this paragraph, it shall indicate which of the criteria were used to determine the level or levels of reporting and explain any subsequent changes in the level of reporting.
(1) Procedures and protocols for sharing by the NAIC only with other state regulators from states in which the insurance group has domiciled insurance carriers. The agreement must provide that the recipient agrees to maintain the confidentiality and privileged status of the CGAD-related documents, materials or other information and must document the NAIC's legal authority to maintain confidentiality;
(2) A provision that prohibits the NAIC from storing the information shared pursuant to this section in a permanent database after the underlying analysis is completed;
(3) A provision requiring the NAIC to provide prompt notice to the superintendent, in addition to the notice to the domestic insurance carrier or insurance group required by section 216, regarding any subpoena, request for disclosure or request for production of the domestic insurance carrier's or insurance group's CGAD-related information; and
(4) A provision expressly requiring the written consent of the domestic insurance carrier before any information shared pursuant to this section may be made public.
Sec. A-6. 24-A MRSA §1102, sub-§4, as amended by PL 1987, c. 399, §4, is further amended to read:
Sec. A-7. 24-A MRSA §1152, sub-§4, as enacted by PL 1987, c. 399, §14, is amended to read:
Sec. A-8. 24-A MRSA §4134, sub-§1, as amended by PL 1997, c. 592, §70, is further amended to read:
Sec. A-9. 24-A MRSA §4134, sub-§7, as amended by PL 1973, c. 585, §12, is further amended to read:
Sec. A-10. 24-A MRSA §4204-A, sub-§2, as amended by PL 2001, c. 88, §§3 to 5, is further amended to read:
Sec. A-11. 24-A MRSA §4208, as amended by PL 1993, c. 313, §§33 to 35, is further amended to read:
§ 4208. Annual and interim reports
Sec. A-12. 24-A MRSA §4222-B, sub-§5, as amended by PL 2001, c. 88, §6, is further amended to read:
Sec. A-13. 24-A MRSA §4222-B, sub-§§23 and 24 are enacted to read:
Sec. A-14. Corporate governance annual disclosure filing due date. A domestic insurance carrier's initial corporate governance annual disclosure filing pursuant to the Maine Revised Statutes, Title 24-A, section 423-G, is due on June 1, 2018.
PART B
Sec. B-1. 24-A MRSA §221, sub-§1, as amended by PL 1993, c. 313, §2, is further amended to read:
Sec. B-2. 24-A MRSA §222, sub-§2, ¶B-3 is enacted to read:
Sec. B-3. 24-A MRSA §222, sub-§2, ¶D-2, as enacted by PL 1993, c. 313, §8, is amended to read:
(1) For life insurers, the net income or loss after dividends to policyholders and federal income taxes but before the inclusion of net realized capital gains or losses; and
(2) For nonlife insurers, the net income or loss after dividends to policyholders and federal income taxes and net realized capital gains or losses.
Sec. B-4. 24-A MRSA §222, sub-§2, ¶D-6 is enacted to read:
(1) The group has premiums written in at least 3 countries;
(2) The percentage of gross premiums written outside the United States is at least 10% of the insurance holding company system's total gross written premiums; and
(3) Based on a 3-year rolling average, the total assets of the insurance holding company system are at least $50,000,000,000 or the total gross written premiums of the insurance holding company system are at least $10,000,000,000.
Sec. B-5. 24-A MRSA §222, sub-§4-C, ¶C, as enacted by PL 2013, c. 238, Pt. A, §11 and affected by §34, is amended to read:
(1) The name and address of each person by whom or on whose behalf the merger or other acquisition of control is to be effected and:
(a) If the person acquiring control is an individual, the person's principal occupation and all offices and positions held during the past 5 years and any convictions for crimes other than minor traffic violations during the past 10 years; and
(b) If the person acquiring control is not an individual, a report of the nature of its business operations during the past 5 years or for a lesser period the person and any predecessors have been in existence; an informative description of the business intended to be done by the person and the person's subsidiaries; and a list of all individuals who are or who have been selected to become directors or executive officers of the person or who perform or will perform functions appropriate to such positions. The list must include the information required by division (a) for each individual listed;
(2) The source, nature and amount of the consideration used or to be used in effecting the merger or other acquisition of control, a description of any transaction through which funds were or are to be obtained for any such purpose, including any pledge of the insurer's stock or the stock of any of its subsidiaries or controlling affiliates, and the identity of persons furnishing consideration. If a source of consideration is a loan made in the lender's ordinary course of business, the identity of the lender is confidential if the person filing the application so requests;
(3) Fully audited financial information as to the earnings and financial condition of each acquiring person for the preceding 5 fiscal years, or for a lesser period if the acquiring person and any predecessors have been in existence for less than 5 years, and similar unaudited information as of a date not earlier than 90 days before the filing of the application;
(4) Any plans or proposals that each acquiring person may have to liquidate the insurer, to sell its assets or merge or consolidate it with any person or to make any other material change in its business or corporate structure or management;
(5) The number of shares of any security referred to in paragraph A that each acquiring person proposes to acquire, the terms of the offer, request, invitation, agreement or acquisition referred to in paragraph A and a statement as to the method by which the fairness of the proposal was arrived at;
(6) The amount of each class of any security referred to in paragraph A that is beneficially owned or concerning which there is a right to acquire beneficial ownership by each acquiring person;
(7) A full description of any contracts, arrangements or understandings with respect to any security referred to in paragraph A in which any acquiring person is involved, including but not limited to transfer of any of the securities, joint ventures, loan or option arrangements, puts or calls, guarantees of loans, guarantees against loss or guarantees of profits, division of losses or profits or the giving or withholding of proxies. The description must identify the persons with whom the contracts, arrangements or understandings have been entered into;
(8) A description of the purchase by any acquiring person of any security referred to in paragraph A during the 12 calendar months preceding the filing of the application, including the dates of purchase, names of the purchasers and consideration paid or agreed to be paid;
(9) A description of any recommendations to purchase any security referred to in paragraph A made during the 12 calendar months preceding the filing of the application by any acquiring person or by anyone based upon interviews with or at the suggestion of the acquiring person;
(10) Copies of all tender offers for, requests or invitations for tenders of, exchange offers for and agreements to acquire or exchange any securities referred to in paragraph A and copies of any additional related soliciting material that has been distributed;
(11) The terms of any agreement, contract or understanding made or proposed to be made with any broker-dealer as to solicitation of securities referred to in paragraph A for tender and the amount of any fees, commissions or other compensation to be paid to broker-dealers with regard to the solicitation of securities referred to in paragraph A;
(12) An agreement by the person required to file the application to provide the annual enterprise risk report required by subsection 8, paragraph B-1 for as long as control by the person exists;
(13) An acknowledgement by the person required to file the application that the person and all subsidiaries within its control in the insurance holding company system will provide information to the superintendent upon request as necessary to evaluate enterprise risk to the insurer;
(14) A statement as to whether or not the proposed transaction will result in an increase in market share in this State in any line of insurance as specified in the annual statement required to be filed under section 423 for one or more insurers with combined market share greater than 5% and, if so, such further information on the competitive impact of the proposed transaction as the superintendent requires by rule or order; and
(15) Such additional information as the superintendent may prescribe by rule or order.
Sec. B-6. 24-A MRSA §222, sub-§7-C is enacted to read:
(1) Does not have substantial insurance operations in the United States;
(2) Has substantial insurance operations in the United States, but not in this State; or
(3) Has substantial insurance operations in the United States and this State, but the superintendent has determined pursuant to the factors set forth in paragraphs B and G that the other regulatory official is the appropriate groupwide supervisor.
(1) The place of domicile of the insurers within the insurance group that hold the largest share of the group's written premiums, assets or liabilities;
(2) The place of domicile of the top-tiered insurer or insurers in the insurance holding company system of the insurance group;
(3) The location of the executive offices or largest operational offices of the insurance group;
(4) The recommendation made by a regulatory official who is a candidate for designation under the criteria in this paragraph but has notified the superintendent that a different regulatory official would be a more appropriate groupwide supervisor;
(5) Whether another regulatory official is acting or is seeking to act as the groupwide supervisor under a regulatory system that the superintendent determines to be:
(a) Substantially similar to the system of regulation provided under the laws of this State; or
(b) Otherwise sufficient in terms of providing for groupwide supervision, enterprise risk analysis and cooperation with other regulatory officials; and
(6) Whether another regulatory official acting or seeking to act as the groupwide supervisor provides the superintendent with reasonably reciprocal recognition and cooperation.
(1) The insurance group's insurers domiciled in this State holding the largest share of the group's premiums, assets or liabilities; or
(2) This State being the place of domicile of the top-tiered insurer or insurers in the insurance holding company system of the insurance group.
(1) Assess the enterprise risks within the insurance group to ensure that:
(a) The material financial condition and liquidity risks to the members of the insurance group that are engaged in the business of insurance are identified by management; and
(b) Reasonable and effective mitigation measures are in place;
(2) Request, from any member of the insurance group, information necessary and appropriate to assess enterprise risk, including, but not limited to, information about the members of the insurance group regarding:
(a) Governance, risk assessment and management;
(b) Capital adequacy; and
(c) Material intercompany transactions;
(3) Coordinate and, through the authority of the regulatory officials of the jurisdictions where members of the insurance group are domiciled, compel development and implementation of reasonable measures designed to ensure that the insurance group is able to promptly recognize and mitigate enterprise risks to members of the insurance group that are engaged in the business of insurance;
(4) Communicate with other state, federal and international agencies that regulate members of the insurance group and share relevant information subject to the confidentiality provisions of subsection 13-A, through supervisory colleges as set forth in subsection 7-B or otherwise;
(5) Enter into agreements with or obtain documentation from any insurer registered under subsection 8, any member of the insurance group and any other state, federal and international regulatory agencies for members of the insurance group, providing the basis for or otherwise clarifying the superintendent's role as groupwide supervisor, including provisions for resolving disputes with other regulatory officials. Such agreements or documentation may not serve as evidence in any proceeding that any insurer or person within an insurance holding company system not domiciled or incorporated in this State is doing business in this State or is otherwise subject to jurisdiction in this State; and
(6) Other groupwide supervision activities, consistent with the authorities and purposes set out in subparagraphs (1) to (5), as considered necessary by the superintendent.
(1) The superintendent's cooperation is in compliance with the laws of this State; and
(2) The regulatory official acknowledged as the groupwide supervisor also recognizes and cooperates with the superintendent's activities as a groupwide supervisor for other insurance groups as applicable. When such recognition and cooperation is not reasonably reciprocal, the superintendent is authorized to refuse recognition and cooperation.
Sec. B-7. 24-A MRSA §222, sub-§9, ¶A-1, as enacted by PL 2013, c. 238, Pt. A, §21 and affected by §34, is amended to read:
Sec. B-8. 24-A MRSA §222, sub-§9, ¶E, as amended by PL 2013, c. 238, Pt. A, §21 and affected by §34, is further amended to read:
(1) Sales, purchases, exchanges, loans or extensions of credit, guarantees or investments that are equal to or exceed:
(a) With respect to nonlife insurers, the lesser of 3% of the insurer's admitted assets as of December 31st of the preceding year and 25% of surplus to policyholders;
(b) With respect to life insurers, 3% of the insurer's admitted assets as of December 31st of the preceding year; or
(c) With respect to nonprofit hospital and medical service organizations and their 100% controlled affiliates that operate as monoline health insurers or health maintenance organizations, the lesser of 5% of the entity's admitted assets as of December 31st of the preceding year and 25% of surplus to policyholders;
(2) Loans or extensions of credit to any person who is not an affiliate, if the insurer makes the loan or extension of credit with the agreement or understanding that the proceeds in whole or in substantial part are to be used to make loans or extensions of credit to, purchase assets of or make investments in any affiliate of the insurer if the loan, extension of credit, purchase or investment is equal to or exceeds:
(a) With respect to nonlife insurers, the lesser of 3% of the insurer's admitted assets as of December 31st of the preceding year and 25% of surplus to policyholders;
(b) With respect to life insurers, 3% of the insurer's admitted assets as of December 31st of the preceding year; or
(c) With respect to nonprofit hospital and medical service organizations and their 100% controlled affiliates that operate as monoline health insurers or health maintenance organizations, the lesser of 5% of the entity's admitted assets as of December 31st of the preceding year and 25% of surplus to policyholders;
(3) All reinsurance pooling agreements, and all reinsurance agreements in which the reinsurance premium or a change in the insurer's liabilities, or the projected reinsurance premium or a projected change in the insurer's liabilities in any of the next 3 years, equals or exceeds 5% of the insurer's surplus to policyholders, as of December 31st of the preceding year, including those agreements that may require as consideration the transfer of assets from an insurer to a nonaffiliate if an agreement or understanding exists between the insurer and nonaffiliate that any portion of the assets will be transferred to one or more affiliates of the insurer;
(4) All management agreements, cost-sharing arrangements, tax allocation agreements, service contracts and guaranties, with the exception of guaranties that are quantifiable in amount and do not exceed, in the aggregate, the lesser of 0.5% of admitted assets and 10% of surplus as regards policyholders as of December 31st of the preceding year;
(5) Any transactions that are part of a plan or series of like transactions with persons within the holding company system if the purpose of those separate transactions is to avoid the statutory threshold amount and thus avoid the review that would occur otherwise transactions when aggregated over any 12-month period exceed the reporting thresholds of this paragraph. If the superintendent determines that those separate transactions were entered into over any 12-month period for such a purpose, the superintendent may exercise authority for the purpose of avoiding regulatory review by circumventing statutory reporting requirements, that determination is a sufficient basis for disapproving the transactions under this subsection; and
(6) Any other material transactions specified by rule that the superintendent has determined may adversely affect the interests of the insurer's policyholders.
A notice of amendment or modification of a transaction must include the reasons for the change and the financial impact on the domestic insurer. The insurer shall notify the superintendent within 30 days after terminating an agreement previously reported under this paragraph.
The superintendent shall disapprove a transaction that is subject to this paragraph if the transaction violates the standards of this section or other applicable law or adversely affects the interests of policyholders. The superintendent's failure to make a determination on a proposed transaction within 30 days after it has been submitted for review has the effect of an approval, unless the superintendent has issued a notice of adjudicatory hearing on the proposal in accordance with section 230.
Sec. B-9. 24-A MRSA §222, sub-§11-C, ¶C, as enacted by PL 2009, c. 511, Pt. A, §5, is amended to read:
(1) For purposes of this subsection, "extraordinary dividend" means any dividend or distribution, other than a pro rata distribution of a class of the insurer’s own securities, that:
(a) Exceeds When aggregated with all other dividends and distributions paid or proposed to be paid by the insurer less than a full year before the payment date, exceeds the greater of 10% of the insurer's surplus to policyholders as of December 31st of the preceding year or and the net gain from operations for the preceding calendar year , whichever is greater;
(b) Is declared within 5 years after any acquisition of control of a domestic insurer or of any person controlling that insurer, unless it has been approved by a number of continuing directors equal to a majority of the directors in office immediately preceding that acquisition of control; or
(c) Is not paid entirely from unassigned funds. For purposes of this division, 50% of the net of unrealized capital gains and unrealized capital losses, reduced, but not to less than zero, by that portion of the asset valuation reserve attributable to equity investments, must be excluded from the calculation of unassigned funds.
(2) An insurer may declare an extraordinary dividend on a conditional basis, subject to the superintendent’s approval. A declaration pursuant to this subparagraph does not confer any rights upon stockholders until the superintendent has approved the payment or the 60-day review period has elapsed.
Sec. B-10. 24-A MRSA §222, sub-§13-A, ¶A, as enacted by PL 2013, c. 238, Pt. A, §26 and affected by §34, is amended to read:
(1) Information obtained by the superintendent pursuant to an examination or investigation pursuant to subsection 1-A to the same extent as the information would have been confidential if obtained in an examination or investigation conducted under section 220 or 221;
(2) A registration statement or report filed under subsection 8, including all supporting information;
(3) A report filed under subsection 9, including all supporting information;
(4) A notice of proposed divestiture filed under subsection 4-C, paragraph B, until the divestiture transaction has occurred;
(5) A disclosure of the beneficial owner of securities made by a broker-dealer pursuant to subsection 4-C, paragraph E;
(6) The identity of a lender that is to finance a proposed transaction if declared confidential under subsection 4-C, paragraph C, subparagraph (2);
(7) Information filed in support of any required attestation of risk management or internal controls under subsection 4-C, paragraph C, subparagraph (12) or (13);
(8) A competitive impact statement filed under subsection 4-C, paragraph C, subparagraph (14), including all supporting information;
(8-A) Groupwide supervision information reported or provided to the superintendent under subsection 7-C;
(9) Information obtained under an information-sharing agreement entered into pursuant to this section to the extent that it is protected by the confidentiality provisions of the agreement;
(10) Information obtained pursuant to this section from a jurisdiction other than this State to the extent that it is confidential under the laws of the jurisdiction in which it is normally maintained; and
(11) Information obtained under this section to the extent that it is confidential under other applicable law, including, but not limited to, section 216, section 225 and Title 1, section 402, subsection 3.
Sec. B-11. 24-A MRSA §223, sub-§1, as amended by PL 1991, c. 828, §7, is further amended to read:
(1) A policyholder or claimant under an insurance policy;
(2) A grantor of a mortgage or similar instrument on the examiner's residence to a regulated entity if done under customary terms and in the ordinary course of business;
(3) An investment owner in shares of regulated diversified investment companies; or
(4) A settlor or beneficiary of a "blind trust" into which any otherwise impermissible holdings have been placed.
Sec. B-12. 24-A MRSA §223, sub-§2, as amended by PL 1993, c. 313, §14, is further amended to read:
PART C
Sec. C-1. 24-A MRSA §731-B, sub-§1, ¶D, as amended by PL 2013, c. 238, Pt. B, §6, is further amended to read:
Sec. C-2. 24-A MRSA §731-B, sub-§2-B is enacted to read:
(1) Life insurance policies with guaranteed nonlevel gross premiums or guaranteed nonlevel benefits;
(2) Universal life insurance policies with provisions resulting in the ability of a policyholder to keep a policy in force over a secondary guarantee period;
(3) Variable annuities with guaranteed death or living benefits;
(4) Long-term care insurance policies; or
(5) Other life and health insurance and annuity products for which the National Association of Insurance Commissioners adopts model regulatory requirements with respect to credit for reinsurance.
(1) The valuation of assets or reserve credits;
(2) The amount and forms of acceptable security, in accordance with rules that may supplement or modify the requirements of subsection 3; and
(3) The circumstances pursuant to which credit will be reduced or eliminated.
(1) Policies issued on or after January 1, 2015; or
(2) Risk on policies issued before January 1, 2015 and ceded in connection with the treaty, in whole or in part, on or after January 1, 2015.
(1) Is certified in this State pursuant to subsection 1, paragraph B-2; or
(2) Maintains at least $250,000,000 in capital and surplus as determined in accordance with section 901-A, excluding the impact of any permitted or prescribed practices; and is:
(a) Licensed in at least 26 states; or
(b) Licensed in at least 10 states and licensed or accredited in a total of at least 35 states.
PART D
Sec. D-1. 24-A MRSA §4379, first ¶, as enacted by PL 1969, c. 132, §1, is amended to read:
The priorities in distribution of assets from the insurer's estate shall be to pay unsecured claims, including the unsecured portion of undersecured claims, are in the order as shown in this section. The first $50 of the amount allowed on each claim in the classes under subsections 2 to 3, 4, 4-B, 5 and 6 shall must be deducted from the claim and included in the class under subsection 8. Claims shall may not be cumulated by assignment to avoid application on the $50 deductible provision. Subject to the $50 deductible provision, every claim in each class shall must be paid in full or adequate funds retained for the payment thereof before claims of the next succeeding class receive any payment. No subclasses shall may be established within any class : .
Sec. D-2. 24-A MRSA §4379, sub-§2, as enacted by PL 1969, c. 132, §1, is repealed.
Sec. D-3. 24-A MRSA §4379, sub-§§4-A and 4-B are enacted to read:
Sec. D-4. 24-A MRSA §4379, sub-§5, as enacted by PL 1969, c. 132, §1, is amended to read:
Sec. D-5. 24-A MRSA §4379, sub-§8, ¶A, as enacted by PL 1969, c. 132, §1, is amended to read:
Sec. D-6. 24-A MRSA §4386, sub-§2, ¶A, as enacted by PL 1981, c. 347, is amended to read:
PART E
Sec. E-1. 24-A MRSA §6401, as enacted by PL 1991, c. 828, §33, is amended to read:
§ 6401. Short title
This chapter may be known and cited as the "Maine Business Transacted with Broker-Controlled Producer-controlled Insurer Act."
Sec. E-2. 24-A MRSA §6402, sub-§2, as enacted by PL 1991, c. 828, §33, is repealed.
Sec. E-3. 24-A MRSA §6402, sub-§4, as enacted by PL 1991, c. 828, §33, is amended to read:
Sec. E-4. 24-A MRSA §6402, sub-§5, as enacted by PL 1991, c. 828, §33, is amended to read:
Sec. E-5. 24-A MRSA §6402, sub-§6, as enacted by PL 1991, c. 828, §33, is amended to read:
Sec. E-6. 24-A MRSA §6402, sub-§7, as amended by PL 1997, c. 457, §53 and affected by §55, is further amended to read:
Sec. E-7. 24-A MRSA §6402, sub-§8, as enacted by PL 1991, c. 828, §33, is amended to read:
Sec. E-8. 24-A MRSA §6403, as enacted by PL 1991, c. 828, §33, is amended to read:
§ 6403. Applicability
This Act chapter applies to licensed property or casualty insurers as defined in section 6402, either domiciled in this State or domiciled in a state that is not an accredited state with a substantially similar law in effect. Section 222, to the extent not modified by this chapter, continues to apply to all parties within holding company systems subject to this chapter.
Sec. E-9. 24-A MRSA §6404, as enacted by PL 1991, c. 828, §33, is amended to read:
§ 6404. Minimum standards
(1) The controlling broker producer:
(a) Places insurance only with the controlled insurer, only with the controlled insurer and a member or members of the controlled insurer's holding company system or only with the controlled insurer's parent, affiliate or subsidiary and receives no compensation based upon the amount of premiums written in connection with such insurance; and
(b) Accepts insurance placements only from nonaffiliated subproducers and not directly from insureds; and
(2) The controlled insurer, except for insurance business written through a residual market facility such as the workers' compensation residual market mechanism or the State's automobile assigned risk plan, accepts insurance business only from a controlling broker producer, a producer controlled by the controlled insurer or a producer that is a subsidiary of the controlled insurer.
Sec. E-10. 24-A MRSA §6405, as corrected by RR 1991, c. 2, §94, is amended to read:
§ 6405. Disclosure
Prior to Before the effective date of the any policy placed with a controlled insurer by a controlling producer or a controlling producer's subproducer, the controlling insurer producer shall cause the controlling broker to deliver written notice to the prospective insured disclosing the relationship between the broker producer and the controlled insurer, except that if the business is placed through a subproducer who is not a controlling broker producer, the controlling insurer producer shall cause the controlling broker to retain and enforce a signed commitment from the subproducer that the subproducer is aware of the relationship between the insurer and the controlling broker producer and that the subproducer has notified or will notify the insured.
Sec. E-11. 24-A MRSA §6406, sub-§1, as enacted by PL 1991, c. 828, §33, is repealed and the following enacted in its place:
Sec. E-12. 24-A MRSA §6406, sub-§2, as enacted by PL 1991, c. 828, §33, is amended to read:
Sec. E-13. 24-A MRSA §6406, sub-§3, as enacted by PL 1991, c. 828, §33, is amended to read:
Sec. E-14. 24-A MRSA §6407, as enacted by PL 1991, c. 828, §33, is repealed.
Sec. E-15. Maine Revised Statutes headnote amended; revision clause. In the Maine Revised Statutes, Title 24-A, chapter 77, in the chapter headnote, the words "business transacted with broker-controlled property or casualty insurer" are amended to read "business transacted with producer-controlled property or casualty insurer" and the Revisor of Statutes shall implement this revision when updating, publishing or republishing the statutes.
PART F
Sec. F-1. 24-A MRSA §6456, sub-§2, as amended by PL 1997, c. 81, §8, is repealed and the following enacted in its place:
Sec. F-2. 24-A MRSA §6458, sub-§1, as enacted by PL 1993, c. 634, Pt. A, §1, is amended to read:
The information listed in paragraph A or B may be shared on a confidential basis in accordance with section 216, subsection 5 but may not be made public or be subject to subpoena, other than by the superintendent and then only for the purpose of enforcement actions taken by the superintendent pursuant to this chapter or any other provision of the insurance laws of this State.
Sec. F-3. 24-A MRSA §6458, sub-§3 is enacted to read:
Sec. F-4. 24-A MRSA §6460, sub-§2, as enacted by PL 1993, c. 634, Pt. A, §1, is amended to read:
PART G
Sec. G-1. 24-A MRSA §6701, sub-§5, as amended by PL 2009, c. 335, §§3 and 4, is further amended to read:
Sec. G-2. 24-A MRSA §6701, sub-§12, as enacted by PL 1997, c. 435, §1, is amended to read:
Sec. G-3. 24-A MRSA §6702, sub-§3, ¶C, as enacted by PL 1997, c. 435, §1, is amended to read:
Sec. G-4. 24-A MRSA §6706, sub-§1, ¶C, as enacted by PL 2009, c. 335, §12, is amended to read:
Sec. G-5. 24-A MRSA §6706, sub-§2, ¶D, as enacted by PL 2009, c. 335, §12, is amended to read:
Sec. G-6. 24-A MRSA §6706, sub-§3, as amended by PL 2009, c. 335, §12, is further amended to read:
Sec. G-7. 24-A MRSA §6706, sub-§6, as amended by PL 2013, c. 588, Pt. A, §30, is further amended to read:
Sec. G-8. 24-A MRSA §6707, as amended by PL 1997, c. 583, §4, is further amended to read:
§ 6707. Financial statements and other reports
An actuarial opinion regarding reserves for known claims and claims incurred but not reported, and expenses associated with those claims, must be included in the audited statements. The actuarial opinion must be given by a member of the American Academy of Actuaries or other qualified loss reserve specialist as defined in the annual statement instructions adopted by the National Association of Insurance Commissioners.
Sec. G-9. 24-A MRSA §6715, as amended by PL 1997, c. 583, §5, is further amended to read:
§ 6715. Confidential information
All information submitted to the superintendent pursuant to section 6702, subsection 3 and section 6724, subsection 3 is confidential and is not a public record within the meaning of Title 1, chapter 13, subchapter I 1. Each report or statement filed with the superintendent pursuant to section 6707, except those filed by or with respect to industrial insured groups as defined in section 6701, subsection 8, is confidential and is not a public record within the meaning of Title 1, chapter 13, subchapter I 1. The confidential nature of this information does not limit the ability of the superintendent, in the superintendent's discretion, to disclose such information to a public official in another state, as long as the public official agrees in writing to maintain the confidentiality of such information and the laws of the state in which the public official serves designate such information as confidential.
Sec. G-10. 24-A MRSA §6724, sub-§2, as enacted by PL 2009, c. 335, §23, is amended to read:
Sec. G-11. 24-A MRSA §6724, sub-§4, ¶B, as enacted by PL 2009, c. 335, §23, is amended to read:
Sec. G-12. 24-A MRSA §6724, sub-§4, ¶B-1 is enacted to read:
Sec. G-13. 24-A MRSA §6724, sub-§4, ¶C, as enacted by PL 2009, c. 335, §23, is amended to read:
Sec. G-14. 24-A MRSA §6724, sub-§4, ¶L, as enacted by PL 2009, c. 335, §23, is amended to read: